Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 18, 2026

Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%?

View original at finance.yahoo.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? Daniel J. Englander, Director at Copart, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ursula Capital Partners distributed 40,000 shares to its limited partners on July 13, 2026, and Daniel J. Englander was excluded from this distribution.

    60% confidence

  • Daniel J. Englander holds no shares directly; his remaining interest consists of approximately 511,000 shares held indirectly through Ursula Capital Partners, representing a 0.0552% ownership stake in Copart.

    60% confidence

  • Daniel J. Englander sold 80,000 shares of Copart common stock on July 13, 2026, for a transaction value of $2.2 million.

    60% confidence

  • The shares were sold in multiple transactions at prices ranging from $27.50 to $27.66, with the reported price of $27.55 reflecting the weighted average of these executions.

    60% confidence

  • Copart operates as a global provider of online vehicle auctions with a market capitalization of $25.5 billion as of the July 14, 2026 market close, generating $4.6 billion in trailing twelve-month revenue and $1.6 billion in net income over the same period.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? — Source | Via News | Finance Via News